Drugs / GSK2302024A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01220128 | Apr 2011 → Nov 2014 | breast cancer | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2302024A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01220128 ↗ |
| Known as | WT1 ASCI | “Cohort A will include postmenopausal patients with hormone receptor-positive breast cancer who receive aromatase inhibitor (AI) as neoadjuvant therapy concurrently with...” NCT01220128 ↗ |
| Modality | Protein / enzyme biologic | “recombinant Wilms' tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic)” PMID 28176175 ↗ Feb 2017 |
| Route | Intramuscular | “6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.” NCT01220128 ↗ |